Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

2015203 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Respiratory Medicine

Volume 3, Issue 4, pp. 301-309

Field-Weighted Citation Impact: 23.34